- Home
- QUIK vs CGTX Comparison
QUIK vs CGTX Comparison
Compare QUIK & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QUIK | CGTX |
|---|---|---|
| Founded | 1988 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.8M | 132.4M |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QUIK | CGTX |
|---|---|---|
| Price | $7.18 | $1.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $11.00 | $3.33 |
| AVG Volume (30 Days) | 171.7K | ★ 970.8K |
| Earning Date | 03-03-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,178,999.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $73.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.26 | $0.22 |
| 52 Week High | $9.27 | $3.83 |
Technical Indicators
Market Signals| Indicator | QUIK | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.24 | 32.13 |
| Support Level | $6.38 | $0.98 |
| Resistance Level | $8.60 | $1.18 |
| Average True Range (ATR) | 0.53 | 0.09 |
| MACD | -0.26 | -0.03 |
| Stochastic Oscillator | 9.71 | 11.76 |
Price Performance
Historical ComparisonAbout QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.